- Home
- GDL vs NRXS Comparison
GDL vs NRXS Comparison
Compare GDL & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | GDL | NRXS |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.7M | 78.9M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | GDL | NRXS |
|---|---|---|
| Price | $8.34 | $7.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 10.1K | ★ 222.3K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $7.81 | $1.33 |
| 52 Week High | $8.67 | $7.97 |
Technical Indicators
Market Signals| Indicator | GDL | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 55.50 | 55.19 |
| Support Level | $8.39 | $5.99 |
| Resistance Level | $8.47 | $7.97 |
| Average True Range (ATR) | 0.10 | 0.71 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 67.12 | 53.63 |
Price Performance
Historical ComparisonAbout GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).